0000000000801942

AUTHOR

Lidia Terruso

showing 4 related works from this author

The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-an…

2016

Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of liver metastasis (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Materials and Methods: Data from all published studies reporting survival outcomes (RFS and/or OS) of CRC patients who received resection of CLM, stratified by KRAS and/or BRAF mutation status were collected by sear…

Settore MED/06 - Oncologia MedicaKRAS BRAF prognostic colorectal cancer liver metastasis meta-analysis
researchProduct

The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-an…

2016

OncologySurgical resectionmedicine.medical_specialtybusiness.industryColorectal cancerHematologymedicine.diseasemedicine.disease_causeMetastasisOncologyMeta-analysisInternal medicineMedicineIn patientKRASbusinessAnnals of Oncology
researchProduct

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?

2019

e14035 Background: The immune response to melanoma has been shown to be locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk (infiltrating the entire base of the invasive tumor), non-brisk (infiltrating only focally) and absent. Several studies showed that greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and a higher survival rate. Since recent studies revealed an association between PD-1/PD-L1 expression levels and tumor response, the aim of our study was to investigate the correlation between plasma PD-1 and presence/absence/class of TILs in metastatic melanoma patients. Methods: The plasm…

Cancer ResearchMetastatic melanomaTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemschemical and pharmacologic phenomenamedicine.disease03 medical and health sciences0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesisCancer researchmedicineplasma PD-1 tumor-infiltrating lymphocytes metastatic melanomabusiness030215 immunologyJournal of Clinical Oncology
researchProduct

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

2019

Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent. Several studies have shown that a greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and higher survival rate. Patients and Methods: We investigated by enzyme-linked immunosorbent assay (ELISA) the correlation between PD-1 levels in plasma and the presence/absence of TILs in 28 patients with metastatic melanoma. Results: Low plasma PD-1 levels were correlated with brisk TILs in primary melanoma, whereas intermediate values correlated with the nonbrisk TILs, and hig…

Metastatic melanoma[SDV]Life Sciences [q-bio]plasma PD-1chemical and pharmacologic phenomena[SDV.BC]Life Sciences [q-bio]/Cellular Biologylcsh:RC254-282immune response03 medical and health sciences0302 clinical medicineImmune systembrisk TILmelanomaMedicineIn patientOriginal Researchplasma PD-L1030304 developmental biology0303 health sciencesTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasebrisk TILs3. Good healthOncologytumor-infiltrating lymphocytes030220 oncology & carcinogenesisCancer researchbusinesshuman activitiesTherapeutic Advances in Medical Oncology
researchProduct